Navigation Links
Insulet Reports First Quarter 2008 Results
Date:5/13/2008

earch meeting in

April exploring different routes of administration of its BiTE antibody

MT110 for the treatment of cancer.

* Insulet is an industry partner in a majority of the sites supporting

the Juvenile Diabetes Research Foundation's Artificial Pancreas

Project. As a result of the OmniPod System's role in the project, John

Garibotto, Insulet's Vice President of Research, Development &

Engineering, has been invited to participate in an upcoming

FDA-NIH-JDRF workshop on engineering considerations for building

a closed loop system.

* In the first quarter, Insulet announced two development agreements as

part of the Company's strategy to leverage the OmniPod System for

ongoing innovation. The agreement with DexCom to integrate its

continuous glucose monitoring technology into the wireless, handheld

OmniPod System Personal Diabetes Manager (PDM). The amended agreement

with Abbott Diabetes Care, Inc establishes Abbott's Freestyle blood

glucose monitor will be the exclusive strip meter available in

OmniPod's PDM.

Financial Outlook for 2008

For the full year 2008, Insulet maintains its previously communicated guidance for full year 2008 revenue to be in the range of $40-45 million. The Company also maintains its expected 2008 net operating loss to be in the range of $55-60 million.

Conference Call

Insulet will host a conference call on Tuesday, May 13, 2008 at 5PM Eastern time to discuss the Company's first quarter 2008 results and present information concerning its business, strategies and outlook. To listen to the conference call, please dial 866-277-1182 for domestic callers and 617-597-5359 for international callers. The passcode is 40048264. A replay of the conference call will be available two hours after the start of the call through June 12, 2008 by dialing 888-286-8010 (domestic) an
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
2. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... EUGENE, Ore. -- Scientists, including University of Oregon ... to create scaffolds of self-assembling, synthetic proteins called ... processes. , The accomplishment -- detailed this week ... by the Proceedings of the National Academy ... an alternative design of the two-dimensional peptoid nanosheets ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... The Muscular Dystrophy Association announced today that it ... biotechnology company, to develop and test a "dissociative glucocorticoid" ... (DMD) . (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO ) ... Institutes of Health Therapeutics for Rare and Neglected Diseases ...
... May 3, 2012 ZyGEM Corp. Ltd., a developer ... DNA and other nucleic acids, today announced it has ... distribution of ZyGEM,s DNA and RNA extraction products in ... a leading provider of quantitative real-time PCR (qPCR) services ...
... SEATTLE, May 3, 2012 CMC Biologics, a leading ... technical excellence in process development and cGMP manufacture ... Manufacturing Company of the Year – Large Category.   The ... partnership with Impact Washington, brought together nearly 300 leaders ...
Cached Biology Technology:MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 2MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 3ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 2ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 3CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award 2
(Date:9/2/2014)... losing weight is enough to prevent Type 2 diabetes, don,t ... 2014 issue of The FASEB Journal , ... Type 2 diabetes. This study compared genetically identical twins-one heavier ... the circulating metabolites, including those related to Type 2 diabetes, ... These findings suggest that the onset of this type of ...
(Date:9/2/2014)... birds, also known as perching birds, that migrate by ... do in autumn to reach their destinations. This seasonal ... that only make short migratory flights, says researcher Cecilia ... Behavioral Ecology and Sociobiology . , Nilsson, ... a tracking radar to measure over three years the ...
(Date:9/2/2014)... the last decade in Taiyuan, China, have substantially improved ... greater than 50% reduction in costs associated with loss ... to researchers at the Columbia Center for Children,s Environmental ... the Shanxi Medical University, the Center of Diseases Control ... School of Public Health. , The study is the ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2
... at least 20 percent of adults in the United ... that prevents bones from rubbing together. By studying the ... how the earliest stages of arthritis make the tissue ... running or jumping. The findings could help researchers ...
... ARBOR, Mich. For nearly two years, University of Michigan ... clinical trial of stem cell injections in patients with the ... ALS or Lou Gehrig,s disease. Now, a new ... way for U-M to become the second site in the ...
... sometimes called "hardening of the arteries" is ... countries. A cell-permeable peptide containing the NF-ĸB nuclear localization ... controlling the development of atherosclerotic disease. This study is ... American Journal of Pathology . Atherosclerosis is a ...
Cached Biology News:Hop, skip or jump? Study says no to all of the above 2Hop, skip or jump? Study says no to all of the above 3FDA approves Phase II of stem cell trial for ALS led by U-M's Dr. Eva Feldman 2Cell-permeable peptide shows promise for controlling cardiovascular disease 2
... The Fujifilm Life Science FLA-8000 Fluorescent Image ... in a single laser imaging system. This ... samples labeled with fluorescent dyes or radioisotopes ... most demanding laboratories. Speed, image quality and ...
...
...
... PC, is used to perform runs ... from the Experion automated electrophoresis system. ... and simulated gel views and summarizes ... a Results table. This software is ...
Biology Products: